Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).

Circulation

Institute of Cardiovascular and Medical Sciences (M.M.Y.L., K.A.G., K.J.M.B., G.R., C.B., R.T.C., L.C., K.F.D., N.N.L., K.M., C.J.P., J.R.P., P.W., A.W., A.R., J.J.V.M., P.S.J., M.C.P., N.S., P.B.M.), University of Glasgow, UK.

Published: July 2022

Download full-text PDF	Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.122.059851	DOI Listing

Publication Analysis

Top Keywords

empagliflozin kidney

kidney biochemical

biochemical imaging

imaging outcomes

outcomes patients

patients type

type diabetes

diabetes prediabetes

prediabetes heart

heart failure

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!